MEDVi Review

MEDVi at a glance: one platform, both compounded and brand-name GLP-1

Most GLP-1 telehealth services pick a lane: they either sell cheaper compounded medication or they route you toward brand-name Wegovy and Zepbound. MEDVi is built around the opposite idea. It lets you start on a lower-cost compounded semaglutide or tirzepatide and, if you'd rather move to the FDA-approved branded drug, switch to Wegovy or Zepbound without leaving the platform or rebuilding your care from scratch. If you genuinely don't know yet whether you want to stay compounded for the savings or graduate to a name-brand pen, that flexibility is the single best reason to consider MEDVi.

The flip side is that MEDVi keeps its certifications close to the vest, and the price you see in month one is not the price you keep paying. Both points matter, and we cover them honestly below.

How MEDVi's pricing actually works

MEDVi runs two different pricing structures depending on whether you choose compounded or brand-name medication, and confusing the two is the easiest way to be surprised by your bill.

On the compounded side, the medication is bundled into one program fee. Your monthly cost covers the physician review, your personalized plan, 1:1 guidance, a metabolic report, and the prescription shipped to your door — there's no separate charge for the drug itself. The introductory rate of $249 for the first month of compounded GLP-1 injection is the headline you'll see, but be clear-eyed: refills step up substantially after that, so the first-month figure is a teaser, not your real ongoing cost. Compounded tablets and compounded tirzepatide sit at their own higher tiers. For context, MEDVi's entry price lands near the category median of $170, but the post-promo refill is what you should budget around.

Brand-name Wegovy and Zepbound work differently: those run on a membership-plus-medication model, where you pay a monthly membership and then the cost of the branded drug on top. That can be the right choice if you want the exact FDA-approved product, but it is a meaningfully different (and usually pricier) commitment than the all-in compounded program.

What you're actually paying for

• Compounded program: one bundled fee that includes the medication, clinician review, shipping, and coaching
• Brand program: an approximately ninety-nine-dollar membership fee plus the separate cost of Wegovy or Zepbound
• Included with both: free shipping, no insurance required, and free dietitian visits and care coaching

The medications and who actually dispenses them

MEDVi offers compounded semaglutide as both an injection and an oral tablet, compounded tirzepatide as an injectable, and the brand-name pens Wegovy and Zepbound. The oral tablet option is genuinely useful for needle-averse patients — not every provider offers a swallowable semaglutide — though note that Alabama and California patients are limited to injectables only because of state law.

Where MEDVi earns some credit is transparency about its supply chain. Rather than hiding behind a vague 'licensed pharmacy partner,' the company names the compounding pharmacies it works with: Triad Rx in Daphne, Alabama; Precision Medicine in Bellmore, New York; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas. The medical side is handled by the OpenLoop Health clinician network and CareGLP Affiliated P.C.s. Naming real, locatable US pharmacies and a known telehealth provider group is more disclosure than many compounded-GLP-1 sites offer.

The differentiator: switchability without starting over

The reason to choose MEDVi over a cheaper compounded-only service is optionality. You can begin on compounded semaglutide to control costs, then move to brand-name Zepbound if your insurance situation changes, if supply tightens, or if you simply decide you want the FDA-approved product — all under one account, one clinical record, and one coaching relationship. For people who are still deciding what they want long-term, that removes the friction of switching providers mid-journey. It's a real, specific advantage, not marketing gloss.

Where MEDVi falls short — the honest drawbacks

Two things should give you pause. First, the certification gap: MEDVi does not disclose LegitScript or PCAB accreditation on its site. That doesn't mean its pharmacies are unaccredited, but for a compounded-medication service, the absence of a visible, third-party certification is a fair reason to ask questions before you commit. Second, the price step-up: the attractive first-month compounded injection rate climbs sharply at refill, so anyone shopping purely on that opening number is likely to feel the increase by month two.

• No published LegitScript or PCAB certification — confirm accreditation directly before ordering
• Refill pricing jumps well above the first-month compounded injection offer
• Not available in Mississippi or North Dakota due to telehealth rules
• Alabama and California are injectable-only, no tablets
• Kansas, Indiana, New Mexico, Oklahoma, and West Virginia require a live provider visit before prescribing

Who should choose MEDVi, and who should skip it

Choose MEDVi if you value the freedom to move between compounded and brand-name GLP-1 within one platform, if you want an oral tablet option, and if a bundled program fee with included coaching and free shipping fits how you like to pay. It covers 48 states, so most US patients can access it.

Skip it if you want a service that leads with its accreditations, if you're optimizing purely for the lowest long-term compounded price (the refill rate isn't the cheapest around), or if you live in a state with the synchronous-visit requirement and want a fully asynchronous experience. Compare its ongoing cost against the $170 category median using our scoring methodology before you lock in.

Bottom line

MEDVi is a solid pick for the specific patient who wants a single home for both compounded and brand-name GLP-1 and the ability to switch between them. The pharmacy and clinician disclosure is better than average, and the compounded program's all-in pricing is genuinely convenient. Just go in with eyes open on two fronts: the refill price is the number that matters, not the first-month teaser, and the lack of a visible LegitScript or PCAB stamp is worth a direct question before you hand over a card. Treat it as a flexible, mid-priced option — not the cheapest, and not the most credential-forward — and it can be a smart fit.

For a side-by-side, Wellorithm ($247/month) and Direct Meds ($249/month) are the most comparable options to weigh against MEDVi.